See “Trough level of infliximab is useful for assessing mucosal healing in Crohn’s disease: a prospective cohort study” on page 223.

Supplementary Fig. 2. Comparison of trough levels of infliximab (IFX) between the loss of response (LOR) and remission groups. (A) Assay A and (B) assay B were used to measure trough levels of IFX (TLI) in both the LOR and remission groups. Serum drawn immediately before IFX infusion was used for TLI measurements. Mean TLI values in the LOR and remission groups are 2.4±3.2 µg/mL vs. 5.3±4.2 µg/mL (P<0.0001) with assay A and 2.3±2.7 µg/mL vs. 5.2±3.8 µg/mL (P<0.0001) with assay B, respectively.